Abstract
In a crossover design study, we compared the plasma bactericidal activities of erythromycin estolate (500 mg) and erythromycin ethylsuccinate (600 mg) after administration of a single oral dose to 12 healthy volunteers. Both erythromycin esters displayed very good plasma bactericidal activities against Streptococcus pneumoniae. The median bactericidal titers produced in plasma against Streptococcus pyogenes and Streptococcus pneumoniae were significantly higher with erythromycin estolate than with the ethylsuccinate ester at both 2 and 8 h after dosing (P less than 0.05 by Student's t test). Both erythromycin esters showed rather weak bactericidal activity against Branhamella catarrhalis; a further look at these results indicated that erythromycin estolate presented 50% of the plasma samples at 2 h with bactericidal titers superior or equal to 1:8, versus 11% for the ethylsuccinate ester. Of the 60 plasma bactericidal activity tests performed against Staphylococcus aureus, only 6 (10%) and 3 (5%) exhibited titers of 1:8 or greater for erythromycin estolate and erythromycin ethylsuccinate, respectively. Clinical trials are warranted in which these products are compared in infections other than Streptococcus pyogenes pharyngitis, for which the clinical superiority of erythromycin estolate has been demonstrated.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Croteau D., Bergeron M. G., LeBel M. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1988 Apr;32(4):561–565. doi: 10.1128/aac.32.4.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Croteau D., Vallée F., Bergeron M. G., LeBel M. High-performance liquid chromatographic assay of erythromycin and its esters using electrochemical detection. J Chromatogr. 1987 Aug 7;419:205–212. doi: 10.1016/0378-4347(87)80278-5. [DOI] [PubMed] [Google Scholar]
- Derrick C. W., Dillon H. C., Jr Streptococcal pharyngitis therapy. A comparison of two erythromycin formulations. Am J Dis Child. 1979 Nov;133(11):1146–1148. doi: 10.1001/archpedi.1979.02130110054008. [DOI] [PubMed] [Google Scholar]
- Dibb W. L., Digranes A., Bottolfsen K. L. Effects of carbon dioxide upon the in vitro activity of erythromycin. Acta Pathol Microbiol Immunol Scand B. 1986 Jun;94(3):173–176. doi: 10.1111/j.1699-0463.1986.tb03038.x. [DOI] [PubMed] [Google Scholar]
- Fraser D. G. Selection of an oral erythromycin product. Am J Hosp Pharm. 1980 Sep;37(9):1199–1205. [PubMed] [Google Scholar]
- Ginsburg C. M., McCracken G. H., Jr, Crow S. D., Dildy B. R., Morchower G., Steinberg J. B., Lancaster K. Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations. Am J Dis Child. 1984 Jun;138(6):536–539. doi: 10.1001/archpedi.1984.02140440020004. [DOI] [PubMed] [Google Scholar]
- Ginsburg C. M., McCracken G. H., Jr, Steinberg J. B., Crow S. D., Dildy B. F., Lancaster K., Olsen K. Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate. Pediatr Infect Dis. 1982 Nov-Dec;1(6):384–387. [PubMed] [Google Scholar]
- Jones R. N., Barry A. L., Fuchs P. C., Thornsberry C. Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965). J Clin Microbiol. 1986 Aug;24(2):233–239. doi: 10.1128/jcm.24.2.233-239.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Preston D. A. Microbiological aspects of erythromycin. Pediatr Infect Dis. 1986 Jan-Feb;5(1):120–123. doi: 10.1097/00006454-198601000-00045. [DOI] [PubMed] [Google Scholar]
- Tardrew P. L., Mao J. C., Kenney D. Antibacterial activity of 2'-esters of erythromycin. Appl Microbiol. 1969 Aug;18(2):159–165. doi: 10.1128/am.18.2.159-165.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]